Navigation Links
US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
Date:2/28/2008

ct of management fee reductions and lower utilization of supportive care drugs. The results of fiscal year 2007 also include restructuring and impairment charges of $15.1 million, a debt extinguishment loss of $12.9 million and an unrealized loss of $11.9 million related to our interest rate swap, for which cash flow hedge accounting was discontinued during 2007. In addition, interest expense increased $20.4 million due to higher borrowings outstanding during 2007.

The company currently anticipates that EBITDA for fiscal year 2008 will be approximately $220 million to $230 million. This estimate is a forward-looking statement and is subject to uncertainty including the results of the scheduled March 13, 2008 meeting of the Oncology Drug Advisory Committee of the FDA. The reader should refer to the Company's cautionary advice regarding forward-looking statements appearing elsewhere in this news release and in the Company's filings with the Securities and Exchange Commission.

Cash Flow

During the quarter ended December 31, 2007, operating cash flow provided was $74.2 million, compared to $3.9 million used in operations in the third quarter of 2007 which reflects lower regularly scheduled interest payments and increased receivable collections in the fourth quarter.

The Company generated operating cash flow of $164.7 million during 2007, compared to $20.5 million in 2006. The increase in operating cash flow was primarily due to working capital investments of $113.0 million during the first quarter of 2006, principally for inventory and accounts payable at the Company's distribution center as well as increased receivable collections during the current year.

On November 30, 2007, the company amended its senior secured credit facility to increase the maximum leverage and decrease the minimum interest coverage ratios required under the facility. The amended terms provide flexibility as the company responds to the adverse impact of reduced
'/>"/>

SOURCE US Oncology Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

Related biology technology :

1. Six UK Hospitals Join Together in Using Varian Medical Oncology Information Network
2. Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit
3. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
4. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
5. Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
6. PRA International to Present Audioconference on Oncology Research - Nov. 8
7. IMPAC Medical Systems to Offer Revenue Cycle Inc.s Array of Oncology Products and Services to Customers
8. AG Mednet to Provide Image Network for Southwest Oncology Group
9. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
10. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
11. Oncology Metrics and Cureline Announce Joint Marketing Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Miles Holder, formerly of Micron Research and ... team as Sales/Marketing Manager. Mr. Holder has over 25 ... the graphite industry. , “We are thrilled to be ... Trinkley, VP of Market and Product Development for Graphel ... the graphite industry, along with his proven track record ...
(Date:11/26/2014)... DE (PRWEB) November 26, 2014 ... Heroes recognition reception on December 5, 2014, in San ... meeting. The MPN Heroes event will honor clinicians, caregivers, ... field of myeloproliferative neoplasms (MPNs). , Special guest ... discuss his family's cancer journey at the reception. ...
(Date:11/26/2014)... 25 novembre 2014 Theravalues Corporation est fier ... marché européen au salon Hi Europe 2014 (du ... ). Curcumine la plus biodisponible actuellement ... (non-cristalline) à des ingrédients approuvés par les règlements ... jaune présent dans la racine de curcuma ( ...
(Date:11/26/2014)... /PRNewswrie/ -- Theravalues Corporation annuncia con orgoglio il lancio ... di Hi Europe 2014 (dal 2 al 4 dicembre, ... della curcumina con la maggiore biodisponibilità di sempre, con ... approvati dalle norme europee. La curcumina è ... ( Curcuma longa ) che è stata associata con ...
Breaking Biology Technology:Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3
... Mass., Sept. 6 Boston Scientific,Corporation (NYSE: BSX ... elected Ray Elliott as a Director. Mr. Elliott, ... Inc.,Previously, he served as Chairman, President and Chief Executive ... Zimmer since 1997. Mr. Elliott,has extensive operating and director ...
... Proteon Therapeutics,( http://www.proteontherapeutics.com ), a privately held ... the,medical needs of patients with renal and ... with its current investor syndicate.,Proteon will use ... candidate,PRT-201, into human clinical studies in both ...
... a world leader in,radiation oncology and non-invasive ... radiotherapy, stereotactic radiosurgery and clinical,workflow solutions at ... 2007 meeting in Barcelona, Spain, September 8-13. ... health care,professionals are expected at the Ninth ...
Cached Biology Technology:Boston Scientific Announces Election of Ray Elliott to Its Board of Directors 2Boston Scientific Announces Election of Ray Elliott to Its Board of Directors 3Proteon Therapeutics Completes $12 Million Financing and Hires CFO 2Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability 2Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability 3
(Date:11/4/2014)... (Philadelphia, PA) – Temple University School of Medicine ... Explorations winner, an initiative funded by the Bill ... MPH, Professor of Obstetrics, Gynecology and Reproductive Sciences; ... at Temple University School of Medicine will pursue ... titled "Maternal Blood Biomarkers to Assess Fetal Neurodevelopment.", ...
(Date:11/4/2014)... of Madagascar,s 101 species of lemurs are threatened with ... rainforests they call home. A new study by Rice ... on rainforest tree populations, which raises concerns about the ... rich biodiversity. , A large proportion of trees in ... in turn disperse the seeds of their fruit trees ...
(Date:11/3/2014)... , Nov. 3, 2014  NeuroSigma ® , ... life sciences company focused on commercialization of its ... for the treatment of neurological and neuropsychiatric disorders, ... Property has issued a Notice of Allowance for ... is co-owned by NeuroSigma and the Regents of ...
Breaking Biology News(10 mins):Temple University School of Medicine receives Grand Challenges Explorations grant 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... took a global corps of scientists approximately $500 million and ... the human genome. Five years later, Boston College Biologist Gabor ... analyze half a million DNA sequences in 10 minutes. ... new breed of computer programs able to accurately process the ...
... New Rochelle, NY, March 27, 2008 -Sustaining hope in ... amyotrophic lateral sclerosis (ALS) should be a goal of ... continuum from focusing on the self to concern for ... April issue (Volume 8, Number 3) of Journal of ...
... patient lying on an operating table, while another student conducts ... a real OR or treatment room, except that the patients ... theyre robots., These high-tech, electronically outfitted mannequins are equipment in ... at the Johns Hopkins Outpatient Center in East Baltimore that ...
Cached Biology News:Software developed by Boston College lab delivers speed and accuracy to genome research 2Software developed by Boston College lab delivers speed and accuracy to genome research 3Hope among patients with ALS may take a variety of forms 2Actor-robots 'staff' part of new $5M simulation training center 2
... Wellpro 384, compatible ... automated liquid handling system ... quickly and accurately prepares ... dilutions. The Wellpro ...
...
...
Multidrop DW is a high-speed automated dispenser for Deep Well plates, 1.1 ml test tubes and 96-well plates. Designed for accuracy and precision, the Multidrop DW dispenses up to eight different reag...
Biology Products: